Friday, 15 Nov 2019

You are here

Coexistent Gout Increases Risk in Rheumatoid Arthritis

It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders.  A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.

Subjects from the multicenter Veterans Affairs Rheumatoid Arthritis (VARA) registry were included and assessed for the presence of gout and serum urate (sUA) levels. 

From a total of 1,999 RA patients 17% had elevated sUA levels (>6.8 mg/dl) and 6.1% had a diagnosis of gout.

The presence of moderate hyperuricemia (sUA >6.8‐8 mg/dl) was associated with an increased risk of CVD‐related mortality (HR 1.56; 95% CI 1.11‐2.21), but this association was attenuated and became nonsignificant with adjustments for other comorbidities commonly seen with hyperuricemia. There were no associations of baseline sUA with all‐cause mortality.

Thus there is a small subset of RA patients who may have gout or hyperuricemia and such findings should underscore the need to also manage comorbidities that may contribute to cardiovascular risk.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

Higher Rates of Venous Thromboembolism in Gout

A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.